An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses

Antiviral Research

Volumn 107, Issue 1, 2014, Pages 56-65

  Guo, Fang ^a   Zhao, Xuesen ^a   Gill, Tina ^a   Zhou, Yan ^b   Campagna, Matthew ^a   Wang, Lijuan ^a   Liu, Fei ^a   Zhang, Pinghu ^a   Dipaolo, Laura ^a   Du, Yanming ^c   Xu, Xiaodong ^c   Jiang, Dong ^d   Wei, Lai ^d   Cuconati, Andrea ^c   Block, Timothy M ^a,c   Guo, Ju Tao ^a   Chang, Jinhong ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c BARUCH S BLUMBERG INSTITUTE   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

Antiviral; Dengue virus; High throughput assay; Innate immune modulator

Indexed keywords

1 (6 ETHOXYBENZO[D]THIAZOL 2 YL) 3 (3 METHOXYPHENYL) UREA; ANTIVIRUS AGENT; BETA INTERFERON; FIREFLY LUCIFERASE; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; EMBRYO; ENCEPHALOMYOCARDITIS VIRUS; GENE EXPRESSION; HEK293 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INNATE IMMUNITY; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; SENDAI VIRUS; SIGNAL TRANSDUCTION; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; DRUG SCREENING; GENE FUSION; GENETICS; ISOLATION AND PURIFICATION; PROCEDURES;

ANTIVIRAL AGENTS; ARTIFICIAL GENE FUSION; CELL LINE; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LUCIFERASES, FIREFLY; PROMOTER REGIONS, GENETIC; RNA VIRUSES;

EID: 84901058059     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.04.010     Document Type: Article

References (46)

1. K.J. Blight, J.A. McKeating, and C.M. Rice Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication J. Virol. 76 24 2002 13001 13014
2. J. Chang, T.M. Block, and J.T. Guo Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions Antiviral Res. 99 3 2013 251 260
3. J. Chang, J.T. Guo, D. Jiang, H. Guo, J.M. Taylor, and T.M. Block Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells J. Virol. 82 16 2008 8215 8223
4. J. Chang, W. Schul, T.D. Butters, A. Yip, B. Liu, A. Goh, S.B. Lakshminarayana, D. Alonzi, G. Reinkensmeier, X. Pan, X. Qu, J.M. Weidner, L. Wang, W. Yu, N. Borune, M.A. Kinch, J.E. Rayahin, R. Moriarty, X. Xu, P.Y. Shi, J.T. Guo, and T.M. Block Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo Antiviral Res. 89 1 2011 26 34
5. J. Chang, L. Wang, D. Ma, X. Qu, H. Guo, X. Xu, P.M. Mason, N. Bourne, R. Moriarty, B. Gu, J.T. Guo, and T.M. Block Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses Antimicrob. Agents Chemother. 53 4 2009 1501 1508
6. J. Chang, T.K. Warren, X. Zhao, T. Gill, F. Guo, L. Wang, M.A. Comunale, Y. Du, D.S. Alonzi, W. Yu, H. Ye, F. Liu, J.T. Guo, A. Mehta, A. Cuconati, T.D. Butters, S. Bavari, X. Xu, and T.M. Block Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses Antiviral Res. 98 3 2013 432 440
7. X.W. Cheng, J. Lu, C.L. Wu, L.N. Yi, X. Xie, X.D. Shi, S.S. Fang, H. Zan, H.F. Kung, and M.L. He Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm Respir. Physiol. Neurobiol. 175 1 2011 185 187
8. R.I. Connor, B.K. Chen, S. Choe, and N.R. Landau Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes Virology 206 2 1995 935 944
9. O.J. D'Cruz, T.K. Venkatachalam, C. Mao, S. Qazi, and F.M. Uckun Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase Biol. Reprod. 67 6 2002 1959 1974
10. B. de Chassey, L. Meyniel-Schicklin, A. Aublin-Gex, P. Andre, and V. Lotteau New horizons for antiviral drug discovery from virus-host protein interaction networks Curr Opin Virol 2 5 2012 606 613
11. A.M. Dougherty, H. Guo, G. Westby, Y. Liu, E. Simsek, J.T. Guo, A. Mehta, P. Norton, B. Gu, T. Block, and A. Cuconati A substituted tetrahydro-tetrazolo- pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion Antimicrob. Agents Chemother. 51 12 2007 4427 4437
12. Y. Du, H. Ye, T. Gill, L. Wang, F. Guo, A. Cuconati, J.T. Guo, T.M. Block, J. Chang, and X. Xu N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections Bioorg. Med. Chem. Lett. 23 7 2013 2172 2176
13. J. Fung, C.L. Lai, W.K. Seto, and M.F. Yuen Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B J. Antimicrob. Chemother. 66 12 2011 2715 2725
14. F. Guo, J. Mead, N. Aliya, L. Wang, A. Cuconati, L. Wei, K. Li, T.M. Block, J.T. Guo, and J. Chang RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response PLoS One 7 10 2012 e42583
15. H. Guo, X. Pan, R. Mao, X. Zhang, L. Wang, X. Lu, J. Chang, J.T. Guo, S. Passic, F.C. Krebs, B. Wigdahl, T.K. Warren, C.J. Retterer, S. Bavari, X. Xu, A. Cuconati, and T.M. Block Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses Antimicrob. Agents Chemother. 55 2 2011 478 486
16. J.T. Guo, V.V. Bichko, and C. Seeger Effect of alpha interferon on the hepatitis C virus replicon J. Virol. 75 18 2001 8516 8523
17. M. Habjan, I. Andersson, J. Klingstrom, M. Schumann, A. Martin, P. Zimmermann, V. Wagner, A. Pichlmair, U. Schneider, E. Muhlberger, A. Mirazimi, and F. Weber Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction PLoS One 3 4 2008 e2032
18. J. He, S. Choe, R. Walker, P. Di Marzio, D.O. Morgan, and N.R. Landau Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity J. Virol. 69 11 1995 6705 6711
19. D. Jiang, J.M. Weidner, M. Qing, X.B. Pan, H. Guo, C. Xu, X. Zhang, A. Birk, J. Chang, P.Y. Shi, T.M. Block, and J.T. Guo Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections J. Virol. 84 16 2010 8332 8341
20. B.L. Jilek, M. Zarr, M.E. Sampah, S.A. Rabi, C.K. Bullen, J. Lai, L. Shen, and R.F. Siliciano A quantitative basis for antiretroviral therapy for HIV-1 infection Nat. Med. 18 3 2012 446 451
21. K. Li, Z. Chen, N. Kato, M. Gale Jr., and S.M. Lemon Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes J. Biol. Chem. 280 17 2005 16739 16747
22. Y.M. Loo, and M. Gale Jr. Immune signaling by RIG-I-like receptors Immunity 34 5 2011 680 692
23. Y. Ma-Lauer, J. Lei, R. Hilgenfeld, and A. von Brunn Virus-host interactomes-antiviral drug discovery Curr. Opin. Virol. 2 5 2012 614 621
24. M. Mibayashi, L. Martinez-Sobrido, Y.M. Loo, W.B. Cardenas, M. Gale Jr., and A. Garcia-Sastre Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus J. Virol. 81 2 2007 514 524
25. H. Negishi, T. Osawa, K. Ogami, X. Ouyang, S. Sakaguchi, R. Koshiba, H. Yanai, Y. Seko, H. Shitara, K. Bishop, H. Yonekawa, T. Tamura, T. Kaisho, C. Taya, T. Taniguchi, and K. Honda A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity Proc. Natl. Acad. Sci. U.S.A. 105 51 2008 20446 20451
26. M.B. Ortigoza, O. Dibben, J. Maamary, L. Martinez-Gil, V.H. Leyva-Grado, P. Abreu Jr., J. Ayllon, P. Palese, and M.L. Shaw A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon PLoS Pathog. 8 4 2012 e1002668
27. K.L. Oslund, and N. Baumgarth Influenza-induced innate immunity: regulators of viral replication, respiratory tract pathology & adaptive immunity Future Virol. 6 8 2011 951 962
28. S. Paessler, and D.H. Walker Pathogenesis of the viral hemorrhagic fevers Annu. Rev. Pathol. 8 1 2013 411 440
29. C.J. Paget, K. Kisner, R.L. Stone, and D.C. DeLong Heterocyclic substituted ureas. II. Immunosuppressive and antiviral activity of benzothiazole- and benzoxazoleureas J. Med. Chem. 12 6 1969 1016 1018
30. D. Panda, and S. Cherry Cell-based genomic screening: elucidating virus-host interactions Curr. Opin. Virol. 2 6 2012 778 786
31. T. Pang, M.J. Cardosa, and M.G. Guzman Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS) Immunol. Cell Biol. 85 1 2007 43 45
32. X. Qu, X. Pan, J. Weidner, W. Yu, D. Alonzi, X. Xu, T. Butters, T. Block, J.T. Guo, and J. Chang Inhibitors of Endoplasmic Reticulum {alpha}-Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release Antimicrob. Agents Chemother. 55 3 2011 1036 1044
33. R. Rajsbaum, R.A. Albrecht, M.K. Wang, N.P. Maharaj, G.A. Versteeg, E. Nistal-Villan, A. Garcia-Sastre, and M.U. Gack Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein PLoS Pathog. 8 11 2012 e1003059
34. K.L. Siu, K.H. Kok, M.H. Ng, V.K. Poon, K.Y. Yuen, B.J. Zheng, and D.Y. Jin Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex J. Biol. Chem. 284 24 2009 16202 16209
35. O. Takeuchi, and S. Akira MDA5/RIG-I and virus recognition Curr. Opin. Immunol. 20 1 2008 17 22
36. O. Takeuchi, and S. Akira Pattern recognition receptors and inflammation Cell 140 6 2010 805 820
37. M. Theron, K.J. Huang, Y.W. Chen, C.C. Liu, and H.Y. Lei A probable role for IFN-gamma in the development of a lung immunopathology in SARS Cytokine 32 1 2005 30 38
38. Y. Tong, Y. Zhu, X. Xia, Y. Liu, Y. Feng, X. Hua, Z. Chen, H. Ding, L. Gao, Y. Wang, M.A. Feitelson, P. Zhao, and Z.T. Qi Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection J. Virol. 85 6 2011 2793 2802
39. T. Wang, T. Town, L. Alexopoulou, J.F. Anderson, E. Fikrig, and R.A. Flavell Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis Nat. Med. 10 12 2004 1366 1373
40. N. Wauquier, P. Becquart, C. Padilla, S. Baize, and E.M. Leroy Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis PLoS Negl. Trop. Dis. 4 10 2010 e837
41. P.L. Yang, M. Gao, K. Lin, Q. Liu, and V.A. Villareal Anti-HCV drugs in the pipeline Curr. Opin. Virol. 1 6 2011 607 616
42. M. Yoneyama, M. Kikuchi, K. Matsumoto, T. Imaizumi, M. Miyagishi, K. Taira, E. Foy, Y.M. Loo, M. Gale Jr., S. Akira, S. Yonehara, A. Kato, and T. Fujita Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity J. Immunol. 175 5 2005 2851 2858
43. W. Yu, T. Gill, L. Wang, Y. Du, H. Ye, X. Qu, J.T. Guo, A. Cuconati, K. Zhao, T.M. Block, X. Xu, and J. Chang Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection J. Med. Chem. 55 13 2012 6061 6075
44. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 2 1999 67 73
45. Z. Zhou, N. Wang, S.E. Woodson, Q. Dong, J. Wang, Y. Liang, R. Rijnbrand, L. Wei, J.E. Nichols, J.T. Guo, M.R. Holbrook, S.M. Lemon, and K. Li Antiviral activities of ISG20 in positive-strand RNA virus infections Virology 409 2 2011 175 188
46. Q. Zhu, J.T. Guo, and C. Seeger Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells J. Virol. 77 17 2003 9204 9210